Seniors experiencing memory problems and cognitive decline now have access to a new diagnostic blood test to detect Alzheimer’s disease. Labcorp this week unveiled the first Food and Drug ...

Labcorp Holdings (LH) experienced a 10% price increase in the past month, which aligns with its recent strategic advancements including the launch of Lumipulse® pTau-217/Beta Amyloid 42 Ratio, marking ...

LH launches the first FDA-cleared blood test for Alzheimer's, boosting access to early diagnosis and nudging its stock higher.

Labcorp introduces US FDA approved blood test, Lumipulse pTau-217/Beta Amyloid 42 Ratio for Alzheimer's disease: Burlington, North Carolina Tuesday, August 19, 2025, 14:00 Hrs [IS ...

Prenatal exposure to chlorpyrifos -- mostly attributable to indoor residential spraying for pests, prevalent in inner-city ...

Labcorp has launched the first blood-based in-vitro diagnostic test cleared by the Food and Drug Administration to aid in the diagnosis of Alzheimer's disease.

FutureWise Research today announces the upcoming release of its comprehensive report, Alzheimer’s Disease Diagnostic Market – ...

A cutting-edge diagnostic test is transforming how Alzheimer’s disease is detected, and part of the research behind its approval was conducted by leading experts in UNLV’s Pam Quirk Biomarker ...

Alzheimer’s disease is a devastating condition that affects more than 7 million Americans, according to the Alzheimer’s Association. As the Baby Boomer generation ages, this number is estimated to ...

Labcorp cut a ribbon on its 18th patient service center in West Virginia Thursday. They also held an open house of the new facility.

The blood test, Lumipulse G, for Alzheimer’s Disease, approved in late May, can confirm the disease with 98 percent accuracy, he said.